PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of two dosages of PegIntron
for treating hepatitis B e antigen (HBeAg) positive chronic hepatitis B compared with the
approved dosage, which is PegIntron 1.0 microgram (mcg)/kg given once a week for 24 weeks.
This study compares dosages of (1) 1.5 mcg/kg once a week for 24 weeks and (2) 1.5 mcg/kg
once a week for 48 weeks with the approved dosage. All subjects are followed for 24 weeks
after their treatment ends.